Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 140

1.

Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation.

Savani M, Skubitz KM.

J Pediatr Hematol Oncol. 2018 Jul 24. doi: 10.1097/MPH.0000000000001264. [Epub ahead of print]

PMID:
30045149
2.

The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.

Bertucci F, De Nonneville A, Finetti P, Perrot D, Nilbert M, Italiano A, Le Cesne A, Skubitz KM, Blay JY, Birnbaum D.

Ann Oncol. 2018 Feb 1;29(2):459-465. doi: 10.1093/annonc/mdx699.

PMID:
29069276
3.

Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.

Skubitz KM, Blaes AH, Konety SH, Francis GS.

Cancer Chemother Pharmacol. 2017 Oct;80(4):787-798. doi: 10.1007/s00280-017-3420-8. Epub 2017 Aug 30.

PMID:
28856562
4.

Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.

Samuels BL, Chawla SP, Somaiah N, Staddon AP, Skubitz KM, Milhem MM, Kaiser PE, Portnoy DC, Priebat DA, Walker MS, Stepanski EJ.

Cancer. 2017 Dec 1;123(23):4640-4647. doi: 10.1002/cncr.30926. Epub 2017 Aug 18.

5.

Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor.

Skubitz KM.

Mayo Clin Proc. 2017 Jun;92(6):947-964. doi: 10.1016/j.mayocp.2017.02.012. Review.

PMID:
28578783
6.

Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors.

Skubitz KM, Geschwind K, Xu WW, Koopmeiners JS, Skubitz AP.

J Transl Med. 2016 Feb 13;14:51. doi: 10.1186/s12967-016-0802-3.

7.

Response of Aneurysmal Bone Cyst to Denosumab.

Skubitz KM, Peltola JC, Santos ER, Cheng EY.

Spine (Phila Pa 1976). 2015 Nov;40(22):E1201-4. doi: 10.1097/BRS.0000000000001027.

PMID:
26730528
8.

Gene expression identifies heterogeneity of metastatic behavior among high-grade non-translocation associated soft tissue sarcomas.

Skubitz KM, Skubitz AP, Xu WW, Luo X, Lagarde P, Coindre JM, Chibon F.

J Transl Med. 2014 Jun 20;12:176. doi: 10.1186/1479-5876-12-176.

9.

Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study.

Martin-Broto J, Cleeland CS, Glare PA, Engellau J, Skubitz KM, Blum RH, Ganjoo KN, Staddon A, Dominkus M, Feng A, Qian Y, Braun A, Jacobs I, Chung K, Atchison C.

Acta Oncol. 2014 Sep;53(9):1173-9. doi: 10.3109/0284186X.2014.910313. Epub 2014 May 19.

PMID:
24834795
10.

Giant cell tumor of bone: current treatment options.

Skubitz KM.

Curr Treat Options Oncol. 2014 Sep;15(3):507-18. doi: 10.1007/s11864-014-0289-1. Review.

PMID:
24788576
11.

Lymphoma of the hands in a patient with rheumatoid arthritis: case report.

Gordon MJ, Peterson BA, Skubitz KM.

J Hand Surg Am. 2014 Apr;39(4):728-31. doi: 10.1016/j.jhsa.2014.01.034. Epub 2014 Mar 5.

PMID:
24612835
12.

An unusual case of Ewing sarcoma: a middle-aged woman with multiple recurrences over 36 years.

Gordon MJ, Manivel JC, Cheng EY, Skubitz KM.

J Pediatr Hematol Oncol. 2014 Oct;36(7):e463-4. doi: 10.1097/MPH.0000000000000134.

PMID:
24577550
13.

Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity.

Misemer BS, Skubitz AP, Carlos Manivel J, Schmechel SC, Cheng EY, Henriksen JC, Koopmeiners JS, Corless CL, Skubitz KM.

Cancer Med. 2014 Feb;3(1):81-90. doi: 10.1002/cam4.160. Epub 2013 Nov 26.

14.

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.

Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK, Kirstein MN.

Br J Cancer. 2014 Jan 21;110(2):304-12. doi: 10.1038/bjc.2013.738. Epub 2013 Dec 3.

15.

Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl.

Karras NA, Polgreen LE, Ogilvie C, Manivel JC, Skubitz KM, Lipsitz E.

J Clin Oncol. 2013 Apr 20;31(12):e200-2. doi: 10.1200/JCO.2012.46.4255. Epub 2013 Mar 18. No abstract available.

16.

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.

Mitra AK, Kirstein MN, Khatri A, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK.

Pharmacogenomics. 2012 Jul;13(9):1009-21. doi: 10.2217/pgs.12.81.

PMID:
22838949
17.

Gene expression identifies heterogeneity of metastatic propensity in high-grade soft tissue sarcomas.

Skubitz KM, Francis P, Skubitz AP, Luo X, Nilbert M.

Cancer. 2012 Sep 1;118(17):4235-43. doi: 10.1002/cncr.26733. Epub 2012 Jan 17.

18.

Two new synthetic peptides from the N-domain of CEACAM1 (CD66a) stimulate neutrophil adhesion to endothelial cells.

Skubitz KM, Skubitz AP.

Biopolymers. 2011;96(1):25-31. doi: 10.1002/bip.21447.

PMID:
20560140
19.

Conventional protein kinase C plays a critical role in negative regulation of CD98-induced homotypic aggregation.

Cho JY, Katz DR, Skubitz KM, Chain BM.

Tissue Antigens. 2010 Jan;75(1):19-29. doi: 10.1111/j.1399-0039.2009.01389.x. Epub 2009 Nov 6.

PMID:
19895572
20.

Giant cell tumour of bone.

Thomas DM, Skubitz KM.

Curr Opin Oncol. 2009 Jul;21(4):338-44. doi: 10.1097/CCO.0b013e32832c951d. Review.

PMID:
19444102

Supplemental Content

Loading ...
Support Center